WellPoint Seeks More Quality Of Life, Cost Data In Formulary Submissions
Executive Summary
WellPoint's updated formulary submission guidelines aim to give drug companies more detailed advice on submitting information on a drug's cost-effectiveness and its impact on pharmacy and medical budgets, as well as its effectiveness in improving patients' quality of life
You may also be interested in...
CMS Guidance On Desired Data Might Meet The Goals Of Parallel Review More Reasonably, Former Official Gottlieb Suggests
AEI's Scott Gottlieb, a former official at FDA and CMS, offers his insights into the proposed parallel review program during Avalere conference.
WellPoint Plans CER Guidance, Building On Progress With Outcomes Data
WellPoint believes its discussions with drug manufacturers about patient outcomes have improved in the 18 months since it published technology assessment criteria focusing on that topic. Now it is updating its criteria to include how to submit results from comparative effectiveness research
WellPoint Plans CER Guidance, Building On Progress With Outcomes Data
WellPoint believes its discussions with drug manufacturers about patient outcomes have improved in the 18 months since it published technology assessment criteria focusing on that topic. Now it is updating its criteria to include how to submit results from comparative effectiveness research